In 2017, the total incident population of Osteosarcoma in 7MM was 2,181. The incident cases of Osteosarcoma in the United States was found to be 1,141 in 2017.
The therapeutic market of Osteosarcoma in 7MM was found to be USD 72.50 million in 2017.
Robust pipeline, increase in incidence and more Immunotherapies into clinical trials are some of the key factors expected to drive the Osteosarcoma Market forward in the coming years.
The key players in the Osteosarcoma Market includes Bayer, Exelixis, Nektar Therapeutics, Eisai, Y-mAbs Therapeutics, GlaxoSmithKline, Novartis, Aadi Bioscience, Vaccinex, Inc., Eleison Pharmaceuticals, Aurora biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb and Cellestia Biotech.
For more detailed information on Osteosarcoma Market, visit:
https://www.delveinsight.com/report-store/osteosarcoma-market